Analysis of the Prognostic Significance of Solute Carrier (SLC) Family 39 Genes in Breast Cancer

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2020 Aug 4

PMID 32744318

Citations 21

Authors

Limei Liu

Jiaomin Yang

Chao Wang

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer (BC) is the most common malignancy in females and remains a main cause of cancer-associated death worldwide. The solute carrier (SLC) groups of membrane transport proteins, which control the influx of zinc, participate in ranging of physiological processes and may provide novel therapeutic targets of cancers. However, the prognostic values of individual SLC family 39 (SLC39A) genes in patients with BC are not clarified.

Materials And Methods: The mRNA expression of SLC family 39 genes in BC was evaluated by using the UALCAN database. The prognostic values of overall survival (OS) of SLC family 39 genes in patients with BC were investigated by Kaplan-Meier plotter. The survival analysis of cells was determined by Project Achilles.

Results: The analytic results suggested that SLC39A1, SLC39A3, SLC39A4, SLC39A5, SLC39A6, SLC39A7, SLC39A9, SLC39A10, SLC39A11 and SLC39A13 were significantly up-regulated in BC tissues compared with normal breast tissues. However, SLC39A8 and SLC39A14 were expressed higher in normal tissues than in BC tissues. High expression of SLC39A2, SLC39A3, SLC39A4, SLC39A5, SLC39A7, SLC39A12 and SLC39A13 was significantly associated with worse OS in patients with BC. In contrast, high mRNA levels of SLC39A6 and SLC39A14 indicated favorable OS. Through subgroup analysis, all abnormal expressed SLC family members were correlated with prognoses of patients with specific BC. Moreover, SLC39A7 was associated with proliferation and cloning of BC.

Conclusions: Our results suggested that SLC family 39 members were promising prognostic biomarkers of BC. The SLC39A7 played a key role in growth and survival of BC cells.

Citing Articles

PGRMC1 and PAQR4 are promising molecular targets for a rare subtype of ovarian cancer.

Kozlowska-Tomczyk K, Borski N, Glod P, Gogola-Mruk J, Ptak A Open Life Sci. 2024; 19(1):20220982.

PMID: 39464509 PMC: 11512499. DOI: 10.1515/biol-2022-0982.

Identification of SLC31A1 as a prognostic biomarker and a target for therapeutics in breast cancer.

Fu H, Dong S, Li K Sci Rep. 2024; 14(1):25120.

PMID: 39448672 PMC: 11502855. DOI: 10.1038/s41598-024-76162-x.

Emerging Perspectives in Zinc Transporter Research in Prostate Cancer: An Updated Review.

Acevedo S, Segovia M, De la Fuente-Ortega E Nutrients. 2024; 16(13).

PMID: 38999774 PMC: 11243615. DOI: 10.3390/nu16132026.

Integrated bioinformatics analysis identifies a Ferroptosis-related gene signature as prognosis model and potential therapeutic target of bladder cancer.

Liu Z, Du D, Zhang S Toxicol Res (Camb). 2024; 13(1):tfae010.

PMID: 38292893 PMC: 10822837. DOI: 10.1093/toxres/tfae010.

A zinc metabolism-related gene signature for predicting prognosis and characteristics of breast cancer.

Hong J, Li M, Chen Y, Du Y, Song D Front Immunol. 2024; 14:1276280.

PMID: 38259456 PMC: 10800782. DOI: 10.3389/fimmu.2023.1276280.

References

Kolenko V, Teper E, Kutikov A, Uzzo R . Zinc and zinc transporters in prostate carcinogenesis. Nat Rev Urol. 2013; 10(4):219-26. PMC: 3702371. DOI: 10.1038/nrurol.2013.43. View

Takatani-Nakase T . Zinc Transporters and the Progression of Breast Cancers. Biol Pharm Bull. 2018; 41(10):1517-1522. DOI: 10.1248/bpb.b18-00086. View

Chen J, Chou F, Yeh S, Ou Z, Shyr C, Huang C . Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated Gαi protein/MAPK/MMP9 intracellular signaling. Oncogene. 2019; 39(3):574-586. DOI: 10.1038/s41388-019-0964-6. View

Torre L, Siegel R, Ward E, Jemal A . Global Cancer Incidence and Mortality Rates and Trends--An Update. Cancer Epidemiol Biomarkers Prev. 2015; 25(1):16-27. DOI: 10.1158/1055-9965.EPI-15-0578. View

Kalyvianaki K, Panagiotopoulos A, Malamos P, Moustou E, Tzardi M, Stathopoulos E . Membrane androgen receptors (OXER1, GPRC6A AND ZIP9) in prostate and breast cancer: A comparative study of their expression. Steroids. 2019; 142:100-108. DOI: 10.1016/j.steroids.2019.01.006. View

Jones H, Goddard L, Gee J, Hiscox S, Rubini M, Barrow D . Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer. 2004; 11(4):793-814. DOI: 10.1677/erc.1.00799. View

Nimmanon T, Ziliotto S, Morris S, Flanagan L, Taylor K . Phosphorylation of zinc channel ZIP7 drives MAPK, PI3K and mTOR growth and proliferation signalling. Metallomics. 2017; 9(5):471-481. PMC: 5451890. DOI: 10.1039/c6mt00286b. View

Hiscox S, Morgan L, Green T, Barrow D, Gee J, Nicholson R . Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat. 2005; 97(3):263-74. DOI: 10.1007/s10549-005-9120-9. View

Zhou H, Liu Y, Wang C, Liu L, Wang H, Zhang Y . Triptolide inhibits Epstein-Barr nuclear antigen 1 expression by increasing sensitivity of mitochondria apoptosis of nasopharyngeal carcinoma cells. J Exp Clin Cancer Res. 2018; 37(1):192. PMC: 6094928. DOI: 10.1186/s13046-018-0865-5. View

10.

Parris T, Danielsson A, Nemes S, Kovacs A, Delle U, Fallenius G . Clinical implications of gene dosage and gene expression patterns in diploid breast carcinoma. Clin Cancer Res. 2010; 16(15):3860-74. DOI: 10.1158/1078-0432.CCR-10-0889. View

11.

Lichten L, Cousins R . Mammalian zinc transporters: nutritional and physiologic regulation. Annu Rev Nutr. 2009; 29:153-76. DOI: 10.1146/annurev-nutr-033009-083312. View

12.

Tsherniak A, Vazquez F, Montgomery P, Weir B, Kryukov G, Cowley G . Defining a Cancer Dependency Map. Cell. 2017; 170(3):564-576.e16. PMC: 5667678. DOI: 10.1016/j.cell.2017.06.010. View

13.

Wenzlau J, Juhl K, Yu L, Moua O, Sarkar S, Gottlieb P . The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A. 2007; 104(43):17040-5. PMC: 2040407. DOI: 10.1073/pnas.0705894104. View

14.

Ding B, Lou W, Xu L, Li R, Fan W . Analysis the prognostic values of solute carrier (SLC) family 39 genes in gastric cancer. Am J Transl Res. 2019; 11(1):486-498. PMC: 6357312. View

15.

Taylor K, Hiscox S, Nicholson R, Hogstrand C, Kille P . Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7. Sci Signal. 2012; 5(210):ra11. PMC: 3428905. DOI: 10.1126/scisignal.2002585. View

16.

Franklin R, Feng P, Milon B, Desouki M, Singh K, Kajdacsy-Balla A . hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol Cancer. 2005; 4:32. PMC: 1243239. DOI: 10.1186/1476-4598-4-32. View

17.

Xu C, Wallace M, Yang J, Jiang L, Zhai Q, Zhang Y . ZIP4 is a novel diagnostic and prognostic marker in human pancreatic cancer: a systemic comparison between EUS-FNA and surgical specimens. Curr Mol Med. 2013; 14(3):309-15. PMC: 6870177. DOI: 10.2174/1566524013666131217112921. View

18.

Taylor K, Vichova P, Jordan N, Hiscox S, Hendley R, Nicholson R . ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer Cells. Endocrinology. 2008; 149(10):4912-20. DOI: 10.1210/en.2008-0351. View

19.

Lyubartseva G, Smith J, Markesbery W, Lovell M . Alterations of zinc transporter proteins ZnT-1, ZnT-4 and ZnT-6 in preclinical Alzheimer's disease brain. Brain Pathol. 2009; 20(2):343-50. PMC: 3175637. DOI: 10.1111/j.1750-3639.2009.00283.x. View

20.

Irizarry R, Wang C, Zhou Y, Speed T . Gene set enrichment analysis made simple. Stat Methods Med Res. 2010; 18(6):565-75. PMC: 3134237. DOI: 10.1177/0962280209351908. View